The growth factor hepatocyte growth factor (HGF), also known as scatter factor, and its tyrosine kinase receptor c-Met play important roles in medulloblastoma malignancy. The transcription factor c-Myc is another contributor to the malignancy of these most common pediatric brain tumors. In the present study, we observed strong morphological similarities between medulloblastoma xenografts overexpressing HGF and medulloblastoma xenografts overexpressing c-Myc. We therefore hypothesized a biologically significant link between HGF/c-Met and c-Myc in medulloblastoma malignancy and studied the molecular and functional interactions between them. We found that HGF induces c-Myc mRNA and protein in established and primary medulloblastoma cells. HGF regulated c-Myc levels via transcriptional and posttranscriptional mechanisms as evidenced by HGF induction of c-Myc promoter activity and induction of c-Myc protein levels in the setting of inhibited transcription and translation. We also found that HGF induces cell cycle progression, cell proliferation, apoptosis and increase in cell size in a c-Myc-dependent manner. Activation of MAPK and PI3K, inhibition of GSK-3b and translocation of b-catenin to the nucleus as well as Tcf/Lef transcriptional activity were involved in mediating c-Myc induction by HGF. Induction of Cdk2 kinase activity was involved in mediating the cell cycle progression effects, and downregulation of Bcl-XL was involved in mediating the proapoptotic effects of HGF downstream of c-Myc. All molecules that mediated the effects of HGF on c-Myc expression, cell proliferation and apoptosis were expressed in human large-cell medulloblastoma tissues. We therefore established for the first time a functional cooperation between HGF/c-Met and c-Myc in human medulloblastoma and elucidated the molecular mechanisms of this cooperation. The findings provide a potential explanation for the high frequency of c-Myc overexpression in medulloblastoma and suggest a cooperative role for c-Met and c-Myc in large-cell anaplastic medulloblastoma formation.
contributor to cell proliferation, differentiation and transformation of human medulloblastoma. [5] [6] [7] [8] [9] [10] c-Myc is activated by genomic amplification in 4-8% of medulloblastoma and such amplification is associated with worse clinical outcome. Overexpression of c-Myc mRNA is observed in 31-64% of medulloblastoma. [11] [12] [13] [14] [15] [16] Therefore, the frequency of c-Myc amplification is not sufficiently high to explain the high frequency of overexpression of c-Myc protein in medulloblastoma. It was suggested that mechanisms other than gene amplification may activate c-Myc transcription in these tumors. In other human tumors, previous observations have revealed that growth factors can induce c-Myc expression. Examples include plateletderived growth factor, which controls c-Myc expression through JNK-, AP-1-and Src-dependent mechanisms. 17, 18 Epidermal growth factor (EGF) induces c-Myc expression in embryonic hamster palate mesenchymal cells. 19 Keratinocyte growth factor or fibroblast growth factor-10 dramatically stimulates the expression of c-Myc protein in a human endometrial carcinoma cell line. 20 However, the mode and mechanisms of c-Myc overexpression in most human medulloblastoma are still unknown.
In the present study, we first observed that the morphology of medulloblastoma xenografts established from HGF-overexpressing DAOY cells strikingly resembles the morphology of xenografts derived from c-Myc-overexpressing DAOY cells as well as the large-cell medulloblastoma subtype that is associated with c-Myc amplification. 21, 22 We therefore hypothesized a biologically significant link between the HGF/ c-Met pathway and c-Myc in human medulloblastoma malignancy and systematically studied the molecular and functional interactions between them. We found that c-Myc expression is regulated by HGF in established and primary medulloblastoma cells and we elucidated the signal-transduction pathways and transcriptional events that are involved in this process. We found that HGF induces cell proliferation, cell cycle progression, apoptosis and cell size increase in medulloblastoma cells in a c-Myc-dependent manner, which involved Cdk2 kinase and Bcl-XL. This study provides insight into the molecular cooperation between c-Met-dependent pathways and c-Myc as well as into the regulation of c-Myc in medulloblastoma. HGF and/or c-Met overexpression in medulloblastoma could explain the high levels of c-Myc in these tumors.
MATERIALS AND METHODS
Cell Culture and Reagents DAOY human medulloblastoma cells were grown in improved minimum essential medium zinc option supplemented with 10% fetal bovine serum (FBS). DAOY-HGF cells overexpressing HGF and DAOY-control cells have been previously described and were grown in zeocin selection medium. 4 ONS-76 cells were grown in RPMI 1640 medium supplemented with 10% FBS. Primary human medulloblastoma cells were isolated from an anaplastic medulloblastoma surgical specimen and grown in neurobasal medium supplemented with EGF (50 ng/ml), bFGF (50 ng/ ml), N-2 supplement and B-27 supplement (Invitrogen, Carlsbad, CA, USA). All cells were grown at 371C in 5% CO 2 / 95% O 2 . The PI3K inhibitor wortmannin, the MAPK inhibitor U0126 and the broad-spectrum caspase inhibitor (Z-VAD-FMK) were obtained from Calbiochem (San Diego, CA, USA). The protein synthesis inhibitor cyclohexamide and the mRNA transcription inhibitor actinomycin D were obtained from Sigma (St Louis, MO, USA). All inhibitors except cyclohexamide and actinomycin D were added for 1 h before the cells were treated with human recombinant HGF (100 ng/ ml) (a kind gift from Genentech Inc.). Cyclohexamide and actinomycin D were added to the cells simultaneously with HGF (100 ng/ml). Camptothecin (CPT) was obtained from Sigma, and Annexin V-PE and Annexin V-FITC were obtained from BD Pharmingen (San Diego, CA, USA).
Vectors and Transfections
Tcf-responsive luciferase reporter plasmid (pTCF-Luc), mutant Tcf-binding sites luciferase reporter plasmid (pTCFMut-Luc), b-catenin expression plasmid pb-catenin and c-Myc promoter-luciferase reporter plasmid (pDel-1-Luc) were kindly provided by Dr Bert Vogelstein, Johns Hopkins University. 23, 24 Tcf/Lef transcription factor decoy oligodeoxynucleotides were designed against the b-catenin/Tcf/Lef consensus binding sequence and scrambled oligodeoxynucleotides were used as control. The decoys were previously tested and shown to inhibit Tcf-Luciferase activity (unpublished data). The Bcl-XL expression vector is a kind gift from Dr Saijun Fan, Lombardi Cancer Center. All cells (50-70% confluence) were transfected with Fugene-6 transfection reagent (Roche, Indianapolis, IN, USA) according to the manufacturer's specifications with a 3:1 ratio of transfection reagent volume to DNA mass.
Adenovirus Infections
Adenoviruses encoding anti-c-Met U1/ribozymes were designed and constructed by us as previously described. 25 Adenovirus vectors encoding c-Myc, the c-Myc dominantnegative MadMyc or GFP were kindly provided by Dr Bert Vogelstein, Johns Hopkins University. 24, 26 An adenovirus vector encoding constitutively active GSK-3bS9A mutant was generated as previously described. 27 This mutant contains a serine-to-alanine substitution at residue 9 and cannot be inhibited by phosphorylation. The cells were infected with adenovirus vectors (MOI ¼ 10) for 24 h prior to treatment with HGF. Adenoviruses expressing GFP only (MOI ¼ 10) were used as control in all adenovirus infection experiments.
Northern Analysis
Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA) following the manufacturer's instructions. Northern analysis was performed as previously reported. 25 Briefly, blots were hybridized with full-length cDNA probes for c-Myc (a gift of C Dang, Johns Hopkins 
Immunoblotting and Immunoprecipitation
Immunoblotting was performed as previously described using antibodies specific for phospho-c-Met, phospho-MAPK, total MAPK, phospho-Akt, total Akt, phospho-GSKa/b, GSKa, GSKb, b-catenin, cleaved-PARP, cleaved-caspase-3, cleaved-caspase-9, Bcl-XL (Cell Signaling Technologies, Danvers, MA, USA), Cdk2, cyclin E, E2F-1, c-Myc (Santa Cruz Biotechnologies, Santa Cruz, CA, USA) and p27 (BD Biosciences, San Jose, CA, USA). 4 Blots were also hybridized with b-actin (Santa Cruz Biotechnologies) as loading control. Blots that did not exhibit protein expression changes of large magnitude were quantified by densitometry on film and quantified protein was expressed relative to b-actin with control set at 1. Immunoprecipitations of cyclin E were used to determine Cdk2 protein levels in cyclin E/ Cdk2 complexes, and were performed as follows. For immunoprecipitation, DAOY cells were plated in 10% FBS medium. The following day, cells were exposed to 0.1% FBS medium and infected with adenoviruses expressing MadMyc or GFP (control) for 24 h prior to treatment with HGF for 24 h. The cells were then lysed with RIPA buffer (1% Igepal, 0.5% sodium deoxycholate and 0.1% SDS in PBS) and lysates were cleared by centrifugation. The protein concentration of the supernatant was determined. Each sample (500 mg of total protein) was subjected to a preclear step with a normal mouse IgG-conjugated agarose beads (Santa Cruz Biotechnologies) for 30 min and then immunoprecipitated with 30 ml cyclin E-conjugated agarose beads (Santa Cruz Biotechnologies) overnight at 41C. The beads were collected by centrifugation, washed five times with lysis buffer, heated to 1001C in Laemmli buffer, and subjected to immunoblotting for Cdk2 as described above.
Immunofluorescence and Immunohistochemistry
The cellular localization of b-catenin was determined by immunofluorescence. DAOY cells were plated on coverslips in 10% FBS medium for 24 h and subsequently exposed to 0.1% FBS medium for 24 h prior to treatment with or without HGF for 30 min. The cells were fixed with 4% paraformaldehyde for 10 min and permeabilized with 7.5% glycine containing 0.5% Triton-100 for overnight. The cells were then incubated with rabbit polyclonal anti-human b-catenin antibody in staining solution (1% BSA with 0.1% NP-40) for 2 h and then incubated with FITC-conjugated donkey anti-rabbit secondary antibody for 30 min. Coverslips were put on slides with Vectashield Antifade solution with DAPI (Vector Laboratories, Burlingame, CA, USA). Immunofluorescent localization of b-catenin was analyzed with an Axiovision fluorescent microscope.
Immunohistochemistry was used to ascertain the expression of key molecules linking c-Met and c-Myc in human large-cell medulloblastoma tissues. Tissue arrays containing multiple sections from 100 cases of embryonal central nervous system tumors including 20 large-cell anaplastic medulloblastoma as well as normal tissues including cerebellum were used for these experiments. The tissue arrays were developed and characterized by Dr Charles Eberhart, Johns Hopkins University. Immunohistochemical staining was performed on a DAKO Autostainer using DAKO DAB þ and substrate as the chromagen. Deparaffinized sections of formalin-fixed tissues were immunostained using antibodies specific for HGF, c-Met and Cdk2 (Santa Cruz Biotechnologies), Akt, MAPK and Bcl-XL (Cell Signaling Technologies) and b-catenin (Epitomics Inc., Burlingame, CA, USA) after 10 mM citrate (pH 6) retrieval in DAKO Pascal Pressure Chamber for 0.5 min. Appropriate negative (no primary antibody) and positive controls (human colon cancer) were stained in parallel with each set of tumors studied.
Luciferase Assays
To measure c-Myc promoter and Tcf/Lef transcriptional activity, DAOY and ONS-76 cells were seeded in six-well plates and transfected as described above with 2 mg of either pDel-1-Luc, pTCF-Luc plasmid DNA, pTCF-Mut-Luc plasmid DNA as negative control or 1 mg of pb-catenin plasmid DNA as positive control. At 24 h after transfection, cells were exposed to 0.1% FBS medium overnight and stimulated with or without HGF for 1-6 h. Cell extracts were prepared with 50 ml reporter lysis buffer (Promega, Madison, WI, USA). Luminescence was measured in 10 ml of cell extract with a luciferase assay system kit (Promega) using a luminometer (Monolight 2010). Activity was expressed as fold change in relative light units per mg of cellular protein as determined by the Coomassie protein assay (Pierce, Rockford, IL, USA).
Propidium Iodide Flow Cytometry
The effects of HGF and c-Myc on cell cycle progression were assessed using propidium iodide (PI) flow cytometry as previously described. 4 Briefly, DAOY or ONS-76 cells were grown in 10% FBS medium for 24 h and subsequently exposed to 0.1% FBS. Both cell types were infected with adenoviruses expressing c-Myc, MadMyc or GFP (control) for 24 h prior to treatment without or with HGF for 24 h. The treated cells were washed with PBS, harvested and fixed in 70% (v/v) ethanol. The cells were then treated with 20 mg of DNase-free RNase and stained with PI. Cell samples were analyzed on a FACscan (Becton-Dickinson, Fullerton, CA, USA).
Annexin V Flow Cytometry
Annexin V flow cytometry was used to test the effect of HGF on radiotherapy-or chemotherapy-induced apoptosis as previously described. 4 Briefly, 1 Â 10 5 DAOY cells were seeded in 35 mm plates in 10% serum and subsequently preincubated with or without HGF for 48 h prior to treatment with CPT (100-500 nM) or g-radiation (20-40 Gy) for 48 h. The fraction of phosphatidylserine-positive cells was determined by flow cytometry using the Annexin V-FITC Detection Kit according to the manufacturer's instructions.
Cell Size Assay
Flow cytometry was used to determine the effects of HGF treatment on cell size in vitro and its dependency on c-Myc. DAOY cells were plated in 10% FBS medium. The following day, the cells were exposed to 0.1% FBS medium and infected with adenoviruses encoding MadMyc or GFP (control) for 24 h prior to treatment with 10 ng/ml HGF for 48 h. The cells were collected and prepared for cell cycle analysis as described above. Cell sizes were analyzed on a FACS Calibur flow cytometer using the parameter mean forward scatter height (FSC-H), which is a measure of relative cell size.
Lactate Dehydrogenase Assays
Lactate dehydrogenase (LDH) assays were performed to further confirm the proapoptotic effect of HGF as previously described. 4 Briefly, 1 Â 10 4 cells per well were plated in 12-well plate. Cells were then preincubated with or without HGF for 48 h in 10% serum and subsequently treated with CPT (100-500 nM) for 48 h. Cells in each well were assayed for LDH release using CytoTox96NonRadioactive Cytotoxicity Assay (Promega). Cells were also pretreated with broadspectrum caspase inhibitor (Z-VAD-FMK, 100 mM) for 1 h prior to incubation with HGF and treatment with CPT (250 nM). The fraction of cell death was determined by LDH assays.
PI and Trypan Blue Staining
The apoptotic effects of HGF and c-Myc were also analyzed by PI and trypan blue staining. DAOY cells were infected with adenoviruses expressing c-Myc, MadMyc or GFP (control) for 24 h as described above and subsequently preincubated with or without HGF for 48 h prior to treatment with CPT (100 nM) for 24 h. MadMyc was also transfected into DAOY-HGF or DAOY-control clones and cells were treated with or without 100 nM CPT. All cells were subsequently stained with trypan blue. The number of dead cells stained with trypan blue was determined by counting with a hemocytometer. To obtain morphological evidence of apoptosis, the cells were stained with a solution of PI in PBS (10 mg/ml). Cell suspensions were mounted on slide glasses and subjected to fluorescence microscopic examination. The dead cells can be identified by positive red fluorescence as PI penetrates the membranes of dying/dead cells and intercalates into the major groove of the DNA and produces a fluorescent adduct.
Growth Curves
To determine the effects of HGF and c-Myc on cell proliferation, 30 000 DAOY cells per well were seeded in six-well plates. At 24 h after infection with adenovirus vectors encoding MadMyc or GFP (control), the cells were treated with or without HGF. The cells were harvested by trypsinization every day for 5 days and counted with a hemocytometer.
Cyclin-Dependent (Cdk2) Kinase Assay A kinase assay was used to determine if c-Myc mediates HGF-induced cell cycle progression via activation of Cdk2 kinase activity in DAOY cells. DAOY cells were treated similar to cyclin E immunoprecipitations described above. Each sample (500 mg of total proteins) was subjected to a preclear step with a normal mouse IgG-conjugated agarose beads (Santa Cruz Biotechnologies) for 30 min and then immunoprecipitated with 30 ml cyclin E-conjugated agarose beads (Santa Cruz Biotechnologies) for 1 h at 41C. The beads were collected by centrifugation, washed three times with lysis buffer and twice with kinase buffer containing 50 mM Tris-Hcl (pH 8.0), 8 mM MgCl 2 , 1 mM DTT and protease inhibitor cocktail, and subsequently incubated for 30 min at 301C in 30 ml of kinase reaction mixture containing 1 mg/ml histone H1, 50 mM ATP (Upstate, Lake placid, NY, USA) and 5 mCi of [g- 32 P]ATP (Amersham-Pharmacia). After the incubation, 6 Â Laemmli loading buffer was added to each sample, the complexes were dissociated by heating to 1001C for 5 min, and the reaction products were subjected to SDS-PAGE. The gel was subsequently dried, and the phosphorylated histone product was visualized and quantified by phosphoimaging (Fujifilm).
Bcl-XL Assays
To determine if Bcl-XL mediates the proapoptotic effects of HGF, Bcl-XL was forcibly overexpressed in DAOY cells prior to determination of the effects of HGF on apoptosis. For this purpose, DAOY cells were seeded in 35 mm plates in 10% FBS. Cells were then cotransfected with 3 mg Bcl-XL cDNA and 1 mg GFP cDNA (3:1) for 6 h. The transfected cells were subsequently treated with HGF for 48 h prior to treatment with CPT (250 nM) for 48 h. Bcl-XL-positive cells were determined via selection for GFP. GFP-positive cells were analyzed for apoptosis with Annexin-PE by flow cytometry according to the manufacturer's instructions.
Statistics
All immunoblots show representative results from at least two experiments. All other experiments were repeated at least three times and the results were expressed as mean ± s.e.m. When appropriate, two group comparisons were analyzed with a t-test and multiple group comparisons were analyzed with a Dunnett's test and P-values were calculated. Po0.05 was considered significant and symbolized by an asterisk in the graphs.
RESULTS

HGF Overexpression in Medulloblastoma Xenografts Mimics the Morphology of c-Myc-Overexpressing Medulloblastoma Xenografts
In a previous study, we established human medulloblastoma xenografts from DAOY cells overexpressing HGF (DAOY-HGF). When the histologic characteristics of these xenografts were examined, they exhibited dramatic morphological changes compared with DAOY-control xenografts. Interestingly, DAOY-HGF xenografts displayed features that somewhat resembled those of DAOY overexpressing c-Myc xenografts as well as those reported in the human large-cell anaplastic medulloblastoma subtype, which possesses the worst prognosis of all medulloblastomas and is associated with c-Myc amplification 21, 28 ( Figure 1 ). DAOY-HGF cells were, however, smaller and had nuclei with rather indistinct nuclear chromatin compared to DAOY-Myc cells, which more closely resembled the large-cell medulloblastoma with larger cells, larger nuclei and more prominent nucleoli than DAOY-HGF.
HGF Induces c-Myc via Transcriptional and Post-Transcriptional Mechanisms
The effects of HGF on c-Myc mRNA and protein were assessed by northern analysis and immunoblotting, respectively. Treatment of DAOY cells with HGF (100 ng/ml) induced c-Myc mRNA levels in a time-dependent manner. The induction of c-Myc mRNA started 15 min after stimulation with HGF and increased more than four-fold after 120 min of stimulation before decreasing to nearly basal levels after 4 h (Figure 2a We have previously shown that HGF allows DAOY and ONS-76 medulloblastoma cells to escape G0/G1 cell cycle arrest induced by serum withdrawal and induces DAOY cell proliferation. 4 Here, we first show that HGF enhances chemotherapy-and radiation-induced apoptosis of DAOY cells. Using Annexin V-FITC flow cytometry as well as an To determine the molecular mechanisms with which c-Myc mediates the effects of HGF on cell cycle progression in DAOY cells, the cell cycle-regulating proteins p27, Cdk2, E2F-1 and cyclin E were examined by quantitative immunoblotting. These proteins were chosen based on our previous work that demonstrated their involvement in HGF-induced G1/S progression in medulloblastoma cells. 4 Overexpression of MadMyc did not significantly change these cell cycle-related protein levels compared to control, and overexpression of MadMyc did not reverse HGF-induced reduction of p27 and induction of Cdk2 (Figure 5a ). This shows that the effects of c-Myc on the cell cycle are not mediated by the change of expression of the above-mentioned cell cycle regulatory proteins. We also assessed the effects of HGF-induced c-Myc on Cdk2/cyclin E complex formation using immunoprecipitation. Neither HGF treatment nor expression of MadMyc changed Cdk2 protein levels in cyclin E/Cdk2 immunoprecipitates, indicating that HGF and c-Myc effects on G0/G1 progression are not due to changes in cyclin E/Cdk2 complex formation (Figure 5b) . However, using a cyclin-dependent Cdk2 kinase activity assay, we found that HGF can activate Cdk2 kinase activity and that kinase activity is almost completely inhibited by overexpression of MadMyc (Figure 5b) . Therefore, c-Myc mediates the effects of HGF on G0/G1 progression partly through modulation of Cdk2 kinase activity.
To further determine the molecular mechanisms with which c-Myc mediates the effects of HGF on apoptosis in DAOY cells, we first examined the effects of HGF and c-Myc on multiple apoptosis-regulating proteins. Using quantitative immunoblotting, we found that HGF enhances CPT-induced reduction of antiapoptotic Bcl-XL protein levels and increases activation of caspase-9 and caspase-3 and the cleavage of PARP in DAOY cells (Figure 5c ). Overexpression of MadMyc reversed the change of these proteins induced by HGF and CPT. In the presence of MadMyc, HGF-induced reduction of Bcl-XL protein levels and activation of caspase-9, caspase-3 and PARP cleavage were inhibited as assessed by quantitative immunoblotting (Figure 5c ). These data indicate that c-Myc mediates the effects of HGF on apoptosis-regulating proteins in DAOY cells. We also found that treatment of DAOY cells with the broad-spectrum caspase inhibitor (Z-VAD-FMK) completely inhibited HGF-mediated induction of CPT-induced cell death (Figure 5d ). This shows that HGF enhances CPT-induced DAOY apoptosis in a caspasedependent manner. To determine the role of Bcl-XL in HGFinduced and c-Myc-induced apoptosis, Bcl-XL was forcibly overexpressed in DAOY cells and the effects of HGF and c-Myc on apoptosis were analyzed by Annexin V-PE flow cytometry. Overexpression of Bcl-XL reduced the fraction of dead cells compared to control and significantly inhibited proapoptotic effect of HGF in DAOY cells (n ¼ 3; Po0.05) (Figure 5d ). This shows that downregulation of the antiapoptotic protein Bcl-XL is involved in mediating the proapoptotic effects of HGF/c-Myc.
HGF, c-Met, Akt, MAPK, b-Catenin, Cdk2 and Bcl-XL are Highly Expressed in Human Medulloblastoma Tumors To determine if key molecules that mediate the effects of HGF on c-Myc expression and functions are also expressed in human medulloblastoma tumors, we assessed protein expression of these molecules in medulloblastoma tissue arrays using immunohistochemistry. All 20 human large-cell medulloblastoma tumor sections present on the tissue array exhibited high to very high expression of all examined proteins as compared to normal human cerebellum control ( Figure 6 ). These findings are consistent with the involvement of these molecules in HGF-induced c-Myc expression and function. We first observed relative histological similarities between DAOY-HGF xenografts and DAOY-c-Myc xenografts. These similarities are also shared with the large-cell anaplastic medulloblastoma subtype and are characterized by large, round neoplastic cells with increased nuclear size and nuclei that are also large with markedly atypical and irregular shapes. The large-cell anaplastic phenotype has been associated with c-Myc amplification and represents the most malignant medulloblastoma subtype. 22, 29 Here, we provide a potential explanation for this observation and study its molecular basis.
Our study identifies HGF as a potent regulator of c-Myc expression in medulloblastoma. In addition to other regulatory mechanisms of c-Myc reported in medulloblastoma, such as genomic amplification of c-Myc, mutation of adenomatous polyposis coli (APC) gene and b-catenin, [30] [31] [32] [33] HGF or c-Met overexpression represents a new mechanism that could explain the high levels of c-Myc in these tumors. In our study, HGF strongly induced c-Myc expression levels in all medulloblastoma cells that we tested. The transient nature of HGF-induced c-Myc expression is probably due to the transient application of recombinant HGF in vitro. Recombinant HGF has a finite life and c-Myc has a short halflife. Therefore, when recombinant HGF is degraded HGFinduced c-Myc levels decrease. However, the above does not apply for human medulloblastoma tumors. We previously reported that HGF and c-Met are frequently overexpressed in human medulloblastoma. Therefore, unlike in vitro where 34 Using a different approach, the authors found that overexpression of c-Met resulted in the development of multiple microscopic foci of neoplasia that failed to progress to full-blown malignancies. But an additional genetic stimulus, overexpression of c-Myc, cooperated with c-Met in mammary tumorigenesis. These in vivo findings, which did not examine the molecular interactions between c-Met and c-Myc, are consistent with and supportive of our findings. HGF has antiapoptotic and cytoprotective effects in many human tumors. [35] [36] [37] [38] [39] [40] [41] We also previously found that HGF has antiapoptotic effects in ONS-76 cells. However, proapoptotic effects of HGF have also been reported in some types of cancer cells. This latter is demonstrated in our study where HGF enhanced chemotherapy-and radiation-induced apoptosis of DAOY cells. HGF has been shown to induce apoptosis in a sarcoma cell line and in liver carcinoma models. [42] [43] [44] [45] HGF activates apoptosis signaling pathways by enhancing the production of ROS and increasing the activity of caspase-3 in Sarcoma 180 cells. 46 Furthermore, HGF can sensitize ovarian carcinoma cells to CDDP-and PTX-induced apoptosis through a caspase-dependent apoptotic pathway. 47 Taken together, the induction of cell cycle progression and cell proliferation as well as apoptosis by HGF via c-Myc in DAOY cells are consistent with our in vivo data that show a marked increase in mitotic rates and extensive apoptosis displayed in DAOY-HGF xenografts, characteristics that are also seen in large-cell anaplastic human tumors. These observations further suggest that the cooperation between the HGF/c-Met pathway and c-Myc in human medulloblastoma might lead to the formation of the most malignant large-cell anaplastic medulloblastomas.
In the present study, we also analyzed the mechanisms that mediate the functional effects of HGF in medulloblastoma downstream of c-Myc. We have previously shown that HGF induces cell cycle progression in medulloblastoma via inhibition of the levels of tumor suppressor p27 and induction of Cdk2 and E2F-1 expression. 4 c-Myc inhibition in DAOY medulloblastoma cells did not affect the expression levels of these cell cycle regulators. Also, c-Myc inhibition did not alter Cdk2 protein levels in cyclin E/Cdk2 complexes. However, c-Myc inhibition did inhibit cyclin-dependent kinase activity induced by HGF. These findings are consistent with previous literature that showed that inhibition of c-Myc with MadMyc in NIH3T3 cells did not cause alterations in the expression levels of cyclin E, Cdk2, p27, cyclin D1 or Cdk4, but that the MadMyc-induced G1 arrest was associated with a strong reduction in cyclin E/Cdk2 kinase activity. 48 Our previous finding that HGF regulates cell cycle progression in medulloblastoma is mediated by changes in the expression of p27 and Cdk2 combined with our present findings that c-Myc-mediated HGF-induced G1 progression is not caused by changes in p27 and Cdk2 expression indicate that HGFmediated induction of cell cycle progression in medulloblastoma has c-Myc-dependent as well as c-Myc-independent components. This could explain the partial inhibition of HGF-induced cell cycle progression and proliferation after inhibition of c-Myc as observed in our study.
In this study, we also show that the proapoptotic effects of HGF are mediated by c-Myc in part via downregulation of Bcl-XL in DAOY cells. Interestingly, HGF was cytoprotective in other medulloblastoma cells that possess dramatically higher Bcl-XL levels compared to DAOY cells. HGF induced c-Myc in these cell lines but was unable to downregulate the high Bcl-XL levels of these cells (data not shown). The proapoptotic effects of HGF could therefore depend on Bcl-XL expression levels in the cells, which when constitutively high cannot be downregulated by c-Myc induction. c-Mycinduced apoptosis regulated by Bcl-XL has been reported in other cell types. In mouse embryo fibroblasts, c-Myc sensitizes the cells to g-radiation via suppression of Bcl-XL expression. Restoration of Bcl-XL protects Myc-expressing cells from g-radiation-induced apoptosis. 49 c-Myc activation also suppresses Bcl-XL mRNA and protein levels in cultures of primary myeloid and lymphoid progenitors. 
